<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156396">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01914692</url>
  </required_header>
  <id_info>
    <org_study_id>nova-0426</org_study_id>
    <nct_id>NCT01914692</nct_id>
  </id_info>
  <brief_title>Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection</brief_title>
  <official_title>Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection —a Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <authority>China: Ministry of Science and Technology</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer radical surgery related complications are common.Somatostatin is a
      conventional medical therapy for bleeding.This study explore the effect of Somatostatin for
      Advanced Gastric Cancer After D2 Lymph Node dissection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>fistula of pancreas</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>number of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>amount of bleeding</measure>
    <time_frame>six months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>amount of bleeding after the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>seroperitoneum</measure>
    <time_frame>six months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>seroperitoneum volum of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infection of incisional wound</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>number of patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>postoperative pancreatitis</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>number of patients</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Gastric Cancer After D2 Lymph Node Dissection</condition>
  <arm_group>
    <arm_group_label>Somatostatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical  therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blank group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Use the normal saline instead of somatostatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin</intervention_name>
    <description>Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.</description>
    <arm_group_label>Somatostatin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. More than eighteen years old

          2. Gastric cancer diagnosed by pathological examination

          3. Be given informed consent

          4. Without diabetes/hyperthyroidism/Damages of functions of heart, liver and
             kidney/Systemic Infection/immunodeficiency

        Exclusion Criteria:

          1. Contraindication of vascular puncture operation

          2. Patients who refused to take part in the programe

          3. Poor compliance of treatment

          4. Malnutrition,BMI＜18

          5. with pancreatectomy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Song Wu, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 31, 2013</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Wang Shaochuan</investigator_full_name>
    <investigator_title>Postgraduate</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
